What this market covers
Procedures and devices that take tissue or fluid samples to check for cancer. Buyers are hospitals, imaging centers and pathology labs.
Typical segments
- Needle biopsy
- Surgical biopsy
- Liquid biopsy
- Image guided biopsy
Source: Eurostat
Why this market is moving now
- Extra-EU import value moved +92% from 2020 to 2025, a direct read on EU demand for sourced supply.
- Supply is concentrated: one country provided a large share of extra-EU imports in 2025.
- US employment in the core industry shifted +4% since 2020.
Key figures
Each figure names the source it came from. Open the source list below to read the quoted line.
| Figure | Value | Year | Source |
|---|---|---|---|
| The EU imported €116.8 million of products under CN code 90183290 (Needles for sutures, used in medical, surgical, dental or veterinary sciences) from outside the EU in 2025. | 116.8 EUR million | 2025 | Eurostat |
| Extra-EU imports of CN 90183290 were up 92% in 2025 compared with 2020 (€61.0 million), calculated from Eurostat values. | +92 % change | 2025 | Eurostat |
| EU exports of CN 90183290 to countries outside the EU were worth €57.3 million in 2025. | 57.3 EUR million | 2025 | Eurostat |
| Trade between EU member states in CN 90183290 (intra-EU arrivals) came to €25.3 million in 2025. | 25.3 EUR million | 2025 | Eurostat |
| United States was the largest non-EU supplier of CN 90183290 to the EU in 2025, with €25.8 million, or 22% of extra-EU imports. | 25.8 EUR million | 2025 | Eurostat |
| EU exports of CN 90183290 to the United States were €21.2 million in 2025. | 21.2 EUR million | 2025 | Eurostat |
| The average value of extra-EU imports of CN 90183290 was €130.63 per kilogram in 2025, calculated from Eurostat value and weight. | 130.63 EUR per kg | 2025 | Eurostat |
| Germany was the largest EU exporter of CN 90183290 to non-EU countries in 2025, at €25.9 million. | 25.9 EUR million | 2025 | Eurostat |
| The EU had 63,227 enterprises in NACE class C3250 (Manufacture of medical and dental instruments and supplies) in 2023. | 63,227 enterprises | 2023 | Eurostat |
| EU enterprises in NACE class C3250 had net turnover of €105.31 billion in 2021. | 105.31 EUR billion | 2021 | Eurostat |
| NACE class C3250 employed 600,000 people across the EU in 2023. | 600,000 persons employed | 2023 | Eurostat |
| The US had 4,547 private establishments in NAICS 339112 (Surgical and medical instrument manufacturing) in 2025. | 4,547 establishments | 2025 | U.S. Bureau of Labor Statistics |
| NAICS 339112 employed an average of 140,413 people in US private industry in 2025. | 140,413 jobs | 2025 | U.S. Bureau of Labor Statistics |
| US employment in NAICS 339112 changed by +4% between 2020 (135,655 jobs) and 2025, calculated from BLS figures. | +4 % change | 2025 | U.S. Bureau of Labor Statistics |
| Average annual pay in US NAICS 339112 was $109,475 in 2025. | 109,475 USD per year | 2025 | U.S. Bureau of Labor Statistics |
| The FDA has recorded 155 510(k) clearances for devices named "biopsy needle". | 155 510(k) clearances | 2026 | U.S. Food and Drug Administration |
| 23 of those clearances were issued from 2021 to 2025. | 23 510(k) clearances | 2025 | U.S. Food and Drug Administration |
| Cook Ireland, Ltd. holds 6 510(k) clearances for devices named "biopsy needle". | 6 510(k) clearances | 2026 | U.S. Food and Drug Administration |
| Biopsys Medical, Inc. holds 5 510(k) clearances for devices named "biopsy needle". | 5 510(k) clearances | 2026 | U.S. Food and Drug Administration |
| Manan Medical Products, Inc. holds 5 510(k) clearances for devices named "biopsy needle". | 5 510(k) clearances | 2026 | U.S. Food and Drug Administration |
| Amedic Usa holds 4 510(k) clearances for devices named "biopsy needle". | 4 510(k) clearances | 2026 | U.S. Food and Drug Administration |
| Wilson-Cook Medical, Inc. holds 4 510(k) clearances for devices named "biopsy needle". | 4 510(k) clearances | 2026 | U.S. Food and Drug Administration |
| C.R. Bard, Inc. holds 3 510(k) clearances for devices named "biopsy needle". | 3 510(k) clearances | 2026 | U.S. Food and Drug Administration |
| PubMed indexed 27 papers mentioning "cancer biopsy" in the title or abstract in 2025. | 27 papers | 2025 | U.S. National Library of Medicine |
Sources and method
The figures on this page come from the public sources listed below. Read how we work.
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
Quoted lines
- Figure 1
DS-045409, reporter EU27_2020, product 90183290, partner EXT_EU27_2020, flow import, 2025, VALUE_IN_EUROS 116812609
- Figure 2
DS-045409, reporter EU27_2020, product 90183290, flow import, 2020 VALUE_IN_EUROS 60986848; 2025 VALUE_IN_EUROS 116812609
- Figure 3
DS-045409, reporter EU27_2020, product 90183290, partner EXT_EU27_2020, flow export, 2025, VALUE_IN_EUROS 57314707
- Figure 4
DS-045409, reporter EU27_2020, product 90183290, partner INT_EU27_2020, flow import, 2025, VALUE_IN_EUROS 25287468
- Figure 5
DS-045409, reporter EU27_2020, product 90183290, partner US, flow import, 2025, VALUE_IN_EUROS 25830050
- Figure 6
DS-045409, reporter EU27_2020, product 90183290, partner US, flow export, 2025, VALUE_IN_EUROS 21151523
- Figure 7
DS-045409, reporter EU27_2020, product 90183290, flow import, 2025, VALUE_IN_EUROS 116812609, QUANTITY_IN_100KG 8942
- Figure 1
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
Quoted lines
- Figure 8
DS-045409, reporter DE, product 90183290, partner EXT_EU27_2020, flow export, 2025, VALUE_IN_EUROS 25939263
- Figure 8
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
Quoted lines
- Figure 9
sbs_ovw_act, geo EU27_2020, nace_r2 C3250, indic_sbs ENT_NR, 2023, 63227
- Figure 10
sbs_ovw_act, geo EU27_2020, nace_r2 C3250, indic_sbs NETTUR_MEUR, 2021, 105308
- Figure 11
sbs_ovw_act, geo EU27_2020, nace_r2 C3250, indic_sbs EMP_NR, 2023, 600000
- Figure 9
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 339112, 2025 (2026-11-04)
Quoted lines
- Figure 12
QCEW 2025 annual, US000, private, NAICS 339112, annual_avg_estabs 4547
- Figure 13
QCEW 2025 annual, US000, private, NAICS 339112, annual_avg_emplvl 140413
- Figure 14
QCEW 2020 annual_avg_emplvl 135655; 2025 annual_avg_emplvl 140413
- Figure 15
QCEW 2025 annual, US000, private, NAICS 339112, avg_annual_pay 109475
- Figure 12
- U.S. Food and Drug Administration: openFDA 510(k) clearances, device_name "biopsy needle" (2026-11-04)
Quoted lines
- Figure 16
openFDA device/510k device_name:"biopsy needle", sum of counts by decision_date = 155
- Figure 17
openFDA device/510k decision_date 2021-2025 count = 23
- Figure 16
- U.S. Food and Drug Administration: openFDA 510(k) clearances by applicant, device_name "biopsy needle" (2026-11-04)
Quoted lines
- Figure 18
applicant.exact "Cook Ireland, Ltd." count 6
- Figure 19
applicant.exact "Biopsys Medical, Inc." count 5
- Figure 20
applicant.exact "Manan Medical Products, Inc." count 5
- Figure 21
applicant.exact "Amedic USA" count 4
- Figure 22
applicant.exact "Wilson-Cook Medical, Inc." count 4
- Figure 23
applicant.exact "C.R. Bard, Inc." count 3
- Figure 18
- U.S. National Library of Medicine: PubMed search "cancer biopsy"[tiab] AND 2025[dp] (2026-11-04)
Quoted lines
- Figure 24
esearch count 27
- Figure 24
Buyers and suppliers
Who buys
- Hospitals
- Pathology laboratories
- Imaging centers
Large non-EU suppliers to the EU
Companies to watch
Cook Ireland, Ltd.
6 FDA 510(k) clearances for devices named "biopsy needle".
Biopsys Medical, Inc.
5 FDA 510(k) clearances for devices named "biopsy needle".
Manan Medical Products, Inc.
5 FDA 510(k) clearances for devices named "biopsy needle".
Amedic Usa
4 FDA 510(k) clearances for devices named "biopsy needle".
Wilson-Cook Medical, Inc.
4 FDA 510(k) clearances for devices named "biopsy needle".
C.R. Bard, Inc.
3 FDA 510(k) clearances for devices named "biopsy needle".
What the full report covers
- 01Executive summary
The answer in one page: size, direction and what moves it - 02Market definition and scope
What is in and out of the European Union market - 03Market size, 2021 to 2025
Historical series and growth rates - 04Outlook to 2031
Base, low and high scenarios with stated assumptions - 05Rules, policy and deadlines
Regulation and programmes that change demand - 06Drivers and barriers
What accelerates or slows adoption, by customer segment - 07Prices, costs and margins
Unit economics where public data allows - 08Competitive landscape
8 to 12 company profiles with recent moves - 09Opportunities and risks
For new entrants, suppliers and investors - 10Method and sources
Every assumption and source, listed
Included with the full report
- PDF report, 40 to 60 pages
- Excel data pack
- Ready-to-use charts
- Method note and assumptions
- Written to order in 5 working days
Frequently asked questions
How big is the EU cancer biopsy market?
There is no single official market total. Eurostat trade data shows the EU imported €116.8 million of goods under CN 90183290 from outside the EU in 2025 and exported €57.3 million.
Where does the EU import cancer biopsy from?
United States was the largest non-EU supplier in 2025. Other large suppliers included Brazil, Colombia, Viet Nam.
What is the average import price of cancer biopsy in the EU?
Dividing Eurostat import value by weight gives about €130.63 per kilogram for CN 90183290 in 2025.
Which EU countries export the most cancer biopsy?
Germany led EU exports to non-EU countries in 2025, followed by France, Netherlands.
How many cancer biopsy devices are cleared by the FDA?
openFDA lists 155 510(k) clearances for devices named biopsy needle.
Which companies hold the most FDA clearances for cancer biopsy?
By 510(k) count: Cook Ireland, Ltd., Biopsys Medical, Inc., Manan Medical Products, Inc., Amedic Usa.
Free sample
Get a free sample of this report
We send the table of contents, two sample chapters and the method note, usually within one working day. You owe us nothing for asking.
- Full table of contents
- Two sample chapters
- Method note and data outline